Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $6.31 Analyst target: $20.00 Upside: 216.96%
NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.
See the full interactive analysis & chart →Informational only — not investment advice.